Novel gene therapy approach for nasopharyngeal carcinoma

Seminars in Cancer Biology

Volumn 12, Issue 6, 2002, Pages 505-515

  Liu, Fei Fei ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Death genes; Gene therapy; Nasopharyngeal carcinoma; Transcriptional regulation; Tumor suppressors; Vectors

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; GANCICLOVIR; LATENT MEMBRANE PROTEIN 2; ONYX 015; PROTEIN DERIVATIVE; PROTEIN EBNA1; PROTEIN FASL; PROTEIN P16; PROTEIN P53; THYMIDINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CYTOLYSIS; DNA MODIFICATION; DRUG DESIGN; EPSTEIN BARR VIRUS; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; IONIZING RADIATION; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NONHUMAN; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

EID: 0036435175     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044579X02000937     Document Type: Conference Paper

References (108)

1. Lee AW, Sze WM, Yau TK, Yeung RM, Chappell R, Fowler JF (2001) Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): Report on 3-year tumor control and normal tissue toxicity. Radiother Oncol 58:121-130
2. Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ, Fu KK (2000) Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: The University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 48:711-722
3. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL (2002) Cancer gene therapy: Scientific basis. Annu Rev Med 53:437-452
4. Gene Therapy Clinical Trials - Charts & Statistics. John Wiley. http://213.80.3.170/trials/index.html
5. Balicki D, Beutler E (2002) Gene therapy of human disease. Medicine (Baltimore) 81:69-86
6. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401
7. Marshall E (2001) Gene therapy. Viral vectors still pack surprises. Science 294:1640
8. Li JH, Li P, Klamut H, Liu F-F (1997) Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines. Clin Cancer Res 3:507-514
9. Li JH, Huang D, Sun BF, Zhang XH, Middledorp J, Klamut H, Liu F-F (2000) The efficacy of ionizing radiation combined with adenoviral-mediated p53 therapy in EBV-positive nasopharyngeal carcinoma. Int J Cancer 87:606-610
10. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7:781-787
11. Smith GL, Moss B (1983) Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25:21-28
12. Verma IM, Somia N (1997) Gene therapy-promises, problems and prospects. Nature 389:239-242
13. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261 [see comments]
14. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS (2001) Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 8:1343-1346
15. Nabel GJ (1999) Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA 96:324-326
16. Zhu N, Liggitt D, Liu Y, Debs R (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209-211
17. Liu Y, Liggitt D, Zhong W, Tu G, Gaensler K, Debs R (1995) Cationic liposome-mediated intravenous gene delivery. J Biol Chem 270:24864-24870
18. Felgner PL, Holm M, Chan H (1989) Cationic liposome mediated transfection. Proc West Pharmacol Soc 32:115-121
19. Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF, Rait A, Chang EH (2001) Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7:723-734
20. Ferber D (2001) Gene therapy. Safer and virus-free? Science 294:1638-1642
21. Isner JM (2002) Myocardial gene therapy. Nature 415:234-239
22. Bergelson J, Cunningham J, Droguett G, Kurt-Jones E, Krithivas A, Hong J, Horwitz M, Crowell R, Finberg R (1997) Isolation of a common receptor for Coxsackie B virus and adenoviruses 2 and 5. Science 275:1320-1323
23. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins avB3 and avB5 promote adenovirus internalization but not virus attachment. Cell 73:309-319
24. Krasnykh VN, Douglas JT, van Beusechem VW (2000) Genetic targeting of adenoviral vectors. Mol Ther 1:391-405
25. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW (1995) Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 96:2775-2782
26. Yu DC, Sakamoto GT, Henderson DR (1999) Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 59:1498-1504
27. Siders WM, Halloran PJ, Fenton RG (1998) Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther 5:281-291
28. Haviv YS, Curiel DT (2001) Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 53:135-154
29. Weichselbaum RR, Kufe DW, Advani SJ, Roizman B (2001) Molecular targeting of gene therapy and radiotherapy. Acta Oncol 40:735-738
30. Brade A, Ngo D, Szmitko P, Li PX, Liu F-F, Klamut H (2000) Heat-directed gene targeting of adenoviral vectors to tumour cells. Cancer Gene Ther 7:1566-1574
31. Blackburn RV, Galoforo SS, Corry PM, Lee YJ (1998) Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 58:1358-1362
32. Marples B, Greco O, Joiner MC, Scott SD (2002) Molecular approaches to chemoradiotherapy. Eur J Cancer 38:231-239
33. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP (2000) Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 7:511-517
34. Weinrib L, Li JH, Donovan J, Huang D, Liu F-F (2001) Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and negative nasopharyngeal carcinoma. Cancer Gene Ther 8:352-360
35. Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M, Ng L, Nye J, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376
36. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH (2000) A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885 [see comments]
37. DeWeese TL, van Der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW (2001) A phase i trial of cv706, a replication-competent, psa selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464-7472
38. Kurihara T, Brough DE, Kovesdi I, Kufe DW (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106:763-771
39. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM (2001) Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther 8:397-404
40. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282:1332-1334
41. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19
42. Spruck III CH, Tsai YC, Huang DP, Yang AS, Rideout III WM, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC, Jones PA (1992) Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52:4787-4790
43. Lo KW, Mok CH, Huang DP, Liu YX, Choi PHK, Lee JCK, Tsao SW (1992) p53 mutation in human nasopharyngeal carcinomas. Anticancer Res 12:1957-1964
44. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B, Cummings BJ, Warde P, Liu F-F (2002) Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 94:1997-2006
45. Sheu LF, Chen A, Tseng HH, Leu FJ, Lin JK, Ho KC, Meng CL (1995) Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol 26:380-386
46. Kouvidou C, Stefanaki K, Dai Y, Tzardi M, Koutsoubi K, Darivianaki K, Karidi E, Rontogianni D, Zois E, Kakolyris S, Georgoulias V, Delides G, Kanavaros P (1997) p21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res 17:2615-2620
47. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S (1998) Expression of bcl-2, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 20:640-644
48. Clayman GL, Frank DK, Bruso PA, Goepfert H (1999) Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5:1715-1722
49. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J, Meyn RE (2001) P53 gene replacement for cancer - Interactions with DNA damaging agents. Acta Oncol 40:739-744
50. Pirollo K, Xu L, Tang W, Chang E (1999) Systemically Delivered, Tumor-targeted wtp53 Gene Therapy in Combination with Radiation Results in Tumor Regression, in American Association for Cancer Research, Philadelphia, PA, April 10-14, p. 203
51. Zeng YX, Prabhu N, Meng R, El-Deiry W (1997) Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int J Oncol 11:221-226
52. Qi V, Weinrib L, Ma N, Li JH, Klamut H, Liu F-F (2001) Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line. Int J Hyperthermia 17:38-47
53. Li JH, Chia M, Shi W, Ngo D, Strathdee CA, Huang D, Klamut H, Liu F-F (2002) Tumour targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 62:171-178
54. Li JH, Lax SA, Kim J, Klamut H, Liu F-F (1999) The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 43:607-616
55. Lax SA, Chia M, Busson P, Klamut HJ, Liu F-F (2001) Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts. Radiother Oncol 61:309-312
56. Chen W, Lee Y, Wang H, Yu GG, Jiao W, Zhou W, Zeng Y (1992) Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene. J Cancer Res Clin Oncol 119:46-48
57. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707 [see comments]
58. Slingerland J, Tannock I (1998) Cell proliferation and cell death, in The Basic Science of Oncology, 3rd Edn (Tannock IF, Hill RP, eds) pp. 134-165. McGraw-Hill, New York
59. Sun Y, Hildesheim A, Lanier AE, Cao Y, Yao KT, Raab-Traub N, Yang CS (1995) No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 10:785-788
60. Lo KW, Huang DP, Lau KM (1995) p16 Gene alterations in nasopharyngeal carcinoma. Cancer Res 55:2039-2043
61. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo J, Lee JCK, Huang D (1996) Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721-2725
62. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8:131-137
63. Shibosawa E, Tsutsumi K, Koizuka I, Hoshikawa M, Takakuwa T (2000) Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 110:93-97
64. Gulley M, Nicholls JM, Schneide BG, Amin MB, Ro JY, Geradts J (1998) Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 152:865-869
65. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee JC, Huang DP (1999) Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 81:1122-1126
66. Lee A, Li J, Liu T, Liu F-F (2001) p16 Gene therapy: A potentially effective therapeutic modality in nasopharyngeal carcinoma (NPC), in Tenth International Cancer Gene Therapy Conference, San Diego, CA, December 12-15, p. S7
67. Cohen JI (2000) Epstein-Barr virus infection. N Engl J Med 343:481-492
68. Fahraeus R, Rymo L, Rhim JS, Klein G (1990) Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345:447-449
69. Wensing B, Farrell PJ (2000) Regulation of cell growth and death by Epstein-Barr virus. Microbes Infect 2:77-84
70. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115
71. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM (1992) The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267:24157-24160
72. Wu CJ, Leu CY, Liu ST, Chow KP, Meng CL, Chang YS (1998) Transcriptional activation of NF-kappa B activity by Epstein-Barr virus (EBV) LMP1 as a selective therapeutic strategy for EBV-associated diseases. Gene Ther 5:905-912
73. Niedobitek G, Agathanggelou A, Nicholls J (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7:165-174
74. Bochkarev A, Barwell JA, Pfuetzner RA, Bochkareva E, Frappier L, Edwards AM (1996) Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 84:791-800
75. Shire K, Ceccarelli DF, Avolio-Hunter TM, Frappier L (1999) EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance. J Virol 73:2587-2595
76. Yates J, Warren N, Reisman D, Sugden B (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81:3806-3810
77. Sugden B, Warren N (1989) A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 63:2644-2649
78. Goldsmith K, Bendell L, Frappier L (1993) Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol 67:3418-3426
79. Kieff E (1996) Epstein-Barr virus and its replication, in Virology, 3rd Edn (Fields B, Knipe D, eds) pp. 2343-2396. Lippincott-Raven Publishers, Philadelphia, PA
80. Judde JG, Spangler G, Magrath I, Bhatia K (1996) Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther 7:647-653
81. Hirai H, Satoh E, Osawa M, Inaba T, Shimazaki C, Kinoshita S, Nakagawa M, Mazda O, Imanishi J (1997) Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun 241:112-118
82. Evans TJ, Brooks L, Farrell PJ (1997) A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers. Gene Ther 4:264-267
83. Kenney S, Ge JQ, Westphal EM, Olsen J (1998) Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: Comparison of two different Epstein-Barr virus-based vectors. Hum Gene Ther 9:1131-1141
84. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC (2000) Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: A potential method for treating EBV-positive malignancies. Cancer Res 60:5781-5788
85. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-348
86. Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317-1322
87. White MK, McCubrey JA (2001) Suppression of apoptosis: Role in cell growth and neoplasia. Leukemia 15:1011-1021
88. Daniel PT (2000) Dissecting the pathways to death. Leukemia 14:2035-2044
89. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K (2001) The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-1032
90. Ashkenazi A, Dixit VM (1998) Death receptors: Signaling and modulation. Science 281:1305-1308
91. Abdulkarim B, Sabri S, Deutsch E, Vaganay S, Marangoni E, Vainchenker W, Bongrand P, Busson P, Bourhis J (2000) Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. Int J Cancer 86:229-237
92. Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nat Med 4:31-36
93. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998) Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205-1213
94. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S (1997) Lethal effect of recombinant human Fas ligand in mice pre-treated with propionibacterium acnes. J Immunol 158:2303-2309
95. Nagata S (1997) Apoptosis by death factor. Cell 88:355-365
96. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, Busson P (1999) Control of apoptosis in Epstein-Barr virus-positive nasopharyngeal carcinoma cells: Opposite effects of CD95 and CD40 stimulation. Cancer Res 59:924-930
97. Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, Drira MM, Busson P, Jlidi R (2000) Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 6:3932-3936
98. Tsai ST, Fang SY, Jin YT, Su IJ, Yang BC (1999) Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol 35:421-424
99. Li JH, Shi W, Chia M, Medin J, Huang D, Klamut H, Yeh WC, Richardson C, Liu F-F (2001) A novel EBV-targeted adenoviral vector utilizing a non-cleavable FasL for nasopharyngeal cancer therapy, in Tenth International Conference on Gene Therapy of Cancer, San Diego, CA, December 13-15
100. Busson P, Ganem GG, Flores P, Mugneret F, Clausse B, Caillou B, Braham K, Wakasugi H, Lipinski M, Tursz T (1988) Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 42:599-606
101. Scholle F, Bendt KM, Raab-Traub N (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74:10681-10689
102. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90:8479-8483
103. Sarac S, Akyol MU, Kanbur B, Poyraz A, Akyol G, Yilmaz T, Sungur A (2001) Bcl-2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol 22:377-382
104. Tsai ST, Jin YT, Leung HW, Wang ST, Tsao CJ, Su IJ (1998) Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 18:2849-2854
105. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61-66
106. Chia M, Li JH, Strathdee C, Huang D, Klamut H, Liu F-F (2001) The successful generation of a novel conditionally replicating adevnorus for nasopharyngeal carcinoma (NPC), in Tenth International Conference on Gene Therapy of Cancer, San Diego, CA, December 13-15
107. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B cells in vivo. Immunity 9:395-404
108. Silver L, Anderson CW (1988) Interaction of human adenovirus serotype 2 with human lymphoid cells. Virology 165:377-387